Indomethacin Prior to Difficult Embryo Transfer is it a Solution?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Giza, Egypt, 12411
- Nile IVF center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infertile patients undergoing IVF cycle with difficult mock embryo transfer
- Early follicular FSH level ≤10 IU/L.
- Tubal, male infertility and unexplained causes of fertility will be recruited.
- Fresh ET.
Exclusion Criteria:
- Repeated IVF failure.
Past history of allergy to NSAID, bronchial asthma , peptic ulcer or inflammatory bowel disease.
- Easy mock embryo transfer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group A (Indomethacin)
All patient had long stimulation protocol and IVF/ICSI.
After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
|
Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
Other Names:
patients received induction with the long agonist stimulation protocol.
Followed by ovum pickup and embryo transfer.
Only those with difficult mock embryo transfer will be recruited in this study.
|
|
Placebo Comparator: Group B (Control)
All patient had long stimulation protocol and IVF/ICSI.
After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
|
patients received induction with the long agonist stimulation protocol.
Followed by ovum pickup and embryo transfer.
Only those with difficult mock embryo transfer will be recruited in this study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implantation rate
Time Frame: 6 weeks
|
the number of total gestational sacs divided by the total number of embryos transferred.
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical pregnancy rate
Time Frame: 6 weeks
|
Presence of fetal pulsations after 2 weeks from the positive pregnancy test.
|
6 weeks
|
|
Ongoing pregnancy rate
Time Frame: 12 weeks
|
Pregnancies continuing beyond 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Sarwat Ahawany, MD, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Reproductive Control Agents
- Gout Suppressants
- Tocolytic Agents
- Indomethacin
Other Study ID Numbers
Other Study ID Numbers
- 12018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.